2023 World Conference on Lung Cancer (Posters)-EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center

EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the outcomes of patients with early-stage EGFR mutated non-small cell lung cancer (NSCLC) who underwent surgical resection at a large academic medical center. The study aimed to evaluate the incidence of early-stage disease and recurrence rates in this patient population. The researchers queried a molecular database for patients diagnosed with EGFR-mutant lung cancer between January 2018 and December 2022. Inclusion criteria included patients with a new diagnosis of EGFR mutated NSCLC who had undergone resection. <br /><br />The results showed that out of 58 patients who met the inclusion criteria, none had experienced disease recurrence at a median follow-up of 13.1 months. The patients had various characteristics, with a majority being female, white, and never-smokers. Most patients underwent sublobar resections, and the common mutations seen were EGFR exon 21 and exon 19 deletions. The majority of patients had early-stage disease, with 45 having pathologic stage I. Nine patients received platinum doublet chemotherapy, and six received osimertinib after chemotherapy.<br /><br />The study highlights the importance of reflex molecular testing in early-stage patients, as all mutations were identified through in-house reflexive next-generation sequencing (NGS). This suggests the utility of this testing even in select early-stage patients. Additionally, the study found that a significant proportion of patients were diagnosed with early-stage EGFR mutated NSCLC despite not being candidates for screening, indicating an unmet need in lung cancer screening guidelines.<br /><br />Overall, the findings suggest positive outcomes for patients with early-stage EGFR mutated NSCLC who undergo surgical resection. However, further follow-up is needed to assess the impact of adjuvant osimertinib on outcomes.

Asset Subtitle

Joseph Fuchs

Meta Tag

Speaker Joseph Fuchs

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

EGFR mutated non-small cell lung cancer

surgical resection

early-stage disease

recurrence rates

molecular database

inclusion criteria

follow-up

sublobar resections

pathologic stage I

osimertinib